| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J J Sramek, E J Frackiewicz, N R Cutle. Review of the acetylcholinesterase inhibitor galanthamine. Expert opinion on investigational drugs. vol 9. issue 10. 2000-12-12. PMID:11060814. |
galanthamine (or galantamine, reminyl) is a tertiary alkaloid acetylcholinesterase inhibitor (achei) which has been approved in several countries for the symptomatic treatment of senile dementia of the alzheimer's type. |
2000-12-12 |
2023-08-12 |
Not clear |
| J Sáez-Valero, M S Barquero, A Marcos, C A McLean, D H Smal. Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry. vol 69. issue 5. 2000-11-21. PMID:11032625. |
altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with alzheimer's disease. |
2000-11-21 |
2023-08-12 |
Not clear |
| J Sáez-Valero, M S Barquero, A Marcos, C A McLean, D H Smal. Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry. vol 69. issue 5. 2000-11-21. PMID:11032625. |
previous studies have shown an abnormality in the glycosylation of acetylcholinesterase (ache) in the csf collected postmortem from patients with alzheimer's disease. |
2000-11-21 |
2023-08-12 |
Not clear |
| W Samuel, M Caligiuri, D Galasko, J Lacro, M Marini, F S McClure, K Warren, D V Jest. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. International journal of geriatric psychiatry. vol 15. issue 9. 2000-11-01. PMID:10984725. |
in several retrospective post-mortem studies, patients meeting clinical criteria for alzheimer's disease (ad) who gained the greatest cognitive benefit from treatment with an acetylcholinesterase (ache) inhibitor were found to have neocortical lewy bodies accompanying classical ad neuropathology. |
2000-11-01 |
2023-08-12 |
human |
| H Shinotoh, H Namba, K Fukushi, S Nagatsuka, N Tanaka, A Aotsuka, S Tanada, T Iri. Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography. Alzheimer disease and associated disorders. vol 14 Suppl 1. 2000-10-17. PMID:10850739. |
brain acetylcholinesterase activity in alzheimer disease measured by positron emission tomography. |
2000-10-17 |
2023-08-12 |
human |
| H Shinotoh, H Namba, K Fukushi, S Nagatsuka, N Tanaka, A Aotsuka, S Tanada, T Iri. Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography. Alzheimer disease and associated disorders. vol 14 Suppl 1. 2000-10-17. PMID:10850739. |
brain acetylcholinesterase activity was measured in 14 patients with alzheimer disease and 14 age-matched control subjects by positron emission tomography with a radioactive acetylcholine analogue. |
2000-10-17 |
2023-08-12 |
human |
| H Shinotoh, H Namba, K Fukushi, S Nagatsuka, N Tanaka, A Aotsuka, S Tanada, T Iri. Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography. Alzheimer disease and associated disorders. vol 14 Suppl 1. 2000-10-17. PMID:10850739. |
this technique may be a powerful tool for early diagnosis of alzheimer disease and also for therapeutic monitoring of acetylcholinesterase inhibitors in alzheimer disease. |
2000-10-17 |
2023-08-12 |
human |
| D E Kuhl, S Minoshima, K A Frey, N L Foster, M R Kilbourn, R A Koepp. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Annals of neurology. vol 48. issue 3. 2000-10-16. PMID:10976649. |
limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living alzheimer cerebral cortex. |
2000-10-16 |
2023-08-12 |
Not clear |
| D E Kuhl, S Minoshima, K A Frey, N L Foster, M R Kilbourn, R A Koepp. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Annals of neurology. vol 48. issue 3. 2000-10-16. PMID:10976649. |
based on surrogate assays of peripheral red blood cells, reports state that widely prescribed doses of donepezil hydrochloride provide nearly complete inhibition of cerebral cortical acetylcholinesterase activity in the treatment of alzheimer's disease (ad). |
2000-10-16 |
2023-08-12 |
Not clear |
| H Shinotoh, H Namba, K Fukushi, S Nagatsuka, N Tanaka, A Aotsuka, T Ota, S Tanada, T Iri. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Annals of neurology. vol 48. issue 2. 2000-08-28. PMID:10939570. |
progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in alzheimer's disease: a positron emission tomography study. |
2000-08-28 |
2023-08-12 |
Not clear |
| H Shinotoh, H Namba, K Fukushi, S Nagatsuka, N Tanaka, A Aotsuka, T Ota, S Tanada, T Iri. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Annals of neurology. vol 48. issue 2. 2000-08-28. PMID:10939570. |
we measured brain acetylcholinesterase activity in 30 patients with alzheimer's disease (ad) and 14 age-matched controls by positron emission tomography (pet) and using a carbon 11-labeled acetylcholine analogue. |
2000-08-28 |
2023-08-12 |
Not clear |
| F I Braginskaia, O M Zorina, N P Pal'mina, V D Gaintseva, E B Burlakova, N D Selezneva, I V Kolykhalov, S I Gavrilov. [Certain biochemical blood markers in the process of cholinergic therapy in Alzheimer's disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 100. issue 6. 2000-08-23. PMID:10900685. |
acetylcholinesterase (ache) activity and parameters of the system of regulation of lipid peroxidation (lpo) were estimated in blood of patients with alzheimer's disease (ad) during therapy with amiridine and gliatiline. |
2000-08-23 |
2023-08-12 |
Not clear |
| M A Kamal, N H Greig, A S Alhomida, A A Al-Jafar. Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. Biochemical pharmacology. vol 60. issue 4. 2000-08-21. PMID:10874131. |
kinetics of human acetylcholinesterase inhibition by the novel experimental alzheimer therapeutic agent, tolserine. |
2000-08-21 |
2023-08-12 |
human |
| M A Kamal, N H Greig, A S Alhomida, A A Al-Jafar. Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. Biochemical pharmacology. vol 60. issue 4. 2000-08-21. PMID:10874131. |
characterization of the kinetic parameters of tolserine, a novel acetylcholinesterase (ache) inhibitor of potential in the therapy of alzheimer's disease, to inhibit purified human erythrocyte ache was undertaken for the first time. |
2000-08-21 |
2023-08-12 |
human |
| H Soreq, S Seidma. Anti-sense approach to anticholinesterase therapeutics. The Israel Medical Association journal : IMAJ. vol 2 Suppl. 2000-08-09. PMID:10909423. |
the acetylcholine-hydrolyzing enzyme, acetylcholinesterase, is the molecular target of approved drugs for alzheimer's disease and myasthenia gravis. |
2000-08-09 |
2023-08-12 |
Not clear |
| M Shapira, A Grant, M Korner, H Sore. Genomic and transcriptional characterization of the human ACHE locus: complex involvement with acquired and inherited diseases. The Israel Medical Association journal : IMAJ. vol 2. issue 6. 2000-08-01. PMID:10897240. |
abnormal levels of the acetylcholinesterase enzyme or aberrations involving the long arm of chromosome 7, harboring the ache gene at 7q22, occur in various diseases such as alzheimer's, parkinson's, and leukemias. |
2000-08-01 |
2023-08-12 |
human |
| L Trabace, T Cassano, L Steardo, C Pietra, G Villetti, K M Kendrick, V Cuom. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. The Journal of pharmacology and experimental therapeutics. vol 294. issue 1. 2000-07-24. PMID:10871311. |
biochemical and neurobehavioral profile of chf2819, a novel, orally active acetylcholinesterase inhibitor for alzheimer's disease. |
2000-07-24 |
2023-08-12 |
rat |
| G Jeyarasasingam, M Yeluashvili, M Qui. Tacrine, a reversible acetylcholinesterase inhibitor, induces myopathy. Neuroreport. vol 11. issue 6. 2000-07-17. PMID:10817586. |
tacrine, an acetylcholinesterase (ache) inhibitor that has been used in the treatment of alzheimer's disease, increases available acetylcholine (ach) levels in the synaptic cleft thereby enhancing the activity of cholinergic pathways. |
2000-07-17 |
2023-08-12 |
rat |
| W F Li. Effects of cholinesterase inhibitors on a two-component chained schedule performance in rats. Neurotoxicology and teratology. vol 22. issue 3. 2000-07-12. PMID:10840182. |
the acetylcholinesterase (ache) inhibitors physostigmine (phy), tacrine (tha), and heptylphysostigmine (hep) have been evaluated as potential therapeutics for treatment of alzheimer's disease (ad) and as prophylactics against organophosphate (op) poisoning. |
2000-07-12 |
2023-08-12 |
rat |
| D Carcenac, C Martin-Hunyadi, M Kiesmann, C Demuynck-Roegel, M Alt, F Kuntzman. [Extra-pyramidal syndrome induced by donepezil]. Presse medicale (Paris, France : 1983). vol 29. issue 18. 2000-07-07. PMID:10862247. |
the cholinergic hypothesis of alzheimer's disease is the basis of a new class of drugs: acetylcholinesterase inhibitors. |
2000-07-07 |
2023-08-12 |
Not clear |